The National Institute of Allergy and Infectious Diseases (NIAID) is supporting efforts to develop a recombinant subunit vaccine against the Category B agent ricin toxin. The current focus is on the toxin's 267- amino acid enzymatic A subunit (RTA). To date, vaccine design has been aimed at making point mutations and site-specific deletions in RTA to attenuate its enzymatic activity so that it is safe for use in humans. Very little attention has been paid to how these mutations may affect B-cell epitopes on RTA that are critical for eliciting protective immunity. It is known that neutralizing antibodies consttute only a very small fraction of the total antibody pool elicited by RTA immunization. The overwhelming antibody response is made up of non- neutralizing and toxin-enhancing antibodies. This fact may explain the relative ineffectiveness of the current lead vaccine candidate to elicit detectable serum neutralizing activity despite high titer anti-toxin antibodies Because serum neutralizing antibody titers are the singular correlate of immunity to ricin, it is essential that RTA-based subunit vaccine stimulate measurable serum neutralizing activities. Unfortunately, in the absence of a comprehensive B-cell epitope map of RTA it is not possible to engineer derivatives RTA in which key protective B-cell epitopes are preserved, while epitopes that give rise to non-neutralizing (or even deleterious) antibodies are eliminated. This applicatio proposes to generate a comprehensive and high-resolution B-cell epitope map of RTA. This will be accomplished using a unique collection of resources, including a large panel of RTA-specific mAbs, as well as a collection of RTA derivatives with mutations in all of the known immunodominant regions of the protein. The proposed research project is significant in that the resulting B-cell epitope map will be used in conjunction with the available structural information about RTA to design novel antigens in which targets of neutralizing antibodies are preserved and presented in a context designed to most effectively elicit protective immunity.
The proposed project will aid in the development of a vaccine against ricin toxin, one of the most deadly toxins known to mankind, and a potential biothreat agent.
|Rudolph, Michael J; Vance, David J; Cheung, Jonah et al. (2014) Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies. J Mol Biol 426:3057-68|
|Herrera, Cristina; Vance, David J; Eisele, Leslie E et al. (2014) Differential neutralizing activities of a single domain camelid antibody (VHH) specific for ricin toxin's binding subunit (RTB). PLoS One 9:e99788|
|O'Hara, Joanne M; Kasten-Jolly, Jane C; Reynolds, Claire E et al. (2014) Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA). Immunol Lett 158:7-13|
|Yermakova, Anastasiya; Klokk, Tove Irene; Cole, Richard et al. (2014) Antibody-mediated inhibition of ricin toxin retrograde transport. MBio 5:e00995|
|Yermakova, Anastasiya; Mantis, Nicholas J (2013) Neutralizing activity and protective immunity to ricin toxin conferred by B subunit (RTB)-specific Fab fragments. Toxicon 72:29-34|
|O'Hara, Joanne M; Mantis, Nicholas J (2013) Neutralizing monoclonal antibodies against ricin's enzymatic subunit interfere with protein disulfide isomerase-mediated reduction of ricin holotoxin in vitro. J Immunol Methods 395:71-8|
|Greene, Christopher J; Chadwick, Chrystal M; Mandell, Lorrie M et al. (2013) LT-IIb(T13I), a non-toxic type II heat-labile enterotoxin, augments the capacity of a ricin toxin subunit vaccine to evoke neutralizing antibodies and protective immunity. PLoS One 8:e69678|